Athira Pharma is a biotechnology business based in the US. Athira Pharma shares (ATHA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.27 – a decrease of 7.43% over the previous week. Athira Pharma employs 26 staff and has a market cap (total outstanding shares value) of 0.00.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.27 |
|---|---|
| 52-week range | $0.22 - $3.67 |
| 50-day moving average | $0.31 |
| 200-day moving average | $0.93 |
| Wall St. target price | $0.55 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.52 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.2386 from 2025-05-07
| 1 week (2025-05-02) | -17.15% |
|---|---|
| 1 month (2025-04-09) | 1.75% |
| 3 months (2025-02-07) | -49.99% |
| 6 months (2024-11-08) | -63.84% |
| 1 year (2024-05-09) | -89.25% |
|---|---|
| 2 years (2023-05-08) | -91.66% |
| 3 years (2022-05-06) | 9.2 |
| 5 years (2020-05-05) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -55.23% |
| Return on equity TTM | -110.77% |
| Profit margin | 0% |
| Book value | $1.15 |
| Market Capitalization | $11.2 million |
TTM: trailing 12 months
We're not expecting Athira Pharma to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Athira Pharma's shares have ranged in value from as little as $0.2195 up to $3.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Athira Pharma's is 3.056. This would suggest that Athira Pharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.
To put Athira Pharma's beta into context you can compare it against those of similar companies.
Athira Pharma, Inc. , clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
See our picks for the best brokers for trading S&P 500 stocks, ETFs, options and futures.
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
These are the stocks to buy when you don’t have much to spend.
Cash sweep accounts let you earn interest on your uninvested cash. Learn how they work and how to choose the best one here.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Thinking of switching from Moomoo? Here are 5 apps like Moomoo that offer valuable benefits
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
Webull is a broker with zero-commission trading and a suite of tools to help you invest.